Status:
COMPLETED
Protective Effect of Ulinastatin Against Negative Inflammatory Response and Organ Dysfunction After Acute Type a Aortic Dissection Surgery (PANDA I)
Lead Sponsor:
Nanjing Medical University
Collaborating Sponsors:
Beijing Anzhen Hospital
Conditions:
Acute Aortic Syndrome
Type a Aortic Dissection
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Acute Aortic Syndrome (AAS) is a common feature of acute aortic wall events, including aortic dissection, intramural hematoma, aortic ulceration and aortic trauma, and occurs in up to 35 cases per 100...
Eligibility Criteria
Inclusion
- The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset;
- Patients with type a acute aortic syndrome confirmed clinically and radiologically and planning to undergo aortic surgery were enrolled.
- The patients' age of 18 years or older.
- Agree to participate in the study and sign the informed consent.
Exclusion
- Patients allergic to Ulinastatin;
- Lactating women and pregnant women;
- Patients with mental diseases;
- Refuse to participate in this study and refuse to sign the informed consent.
Key Trial Info
Start Date :
January 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
203 Patients enrolled
Trial Details
Trial ID
NCT04711889
Start Date
January 1 2021
End Date
June 30 2022
Last Update
December 13 2024
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
The first affiliated hospital of nanjing medical university
Nanjing, Jiangsu, China, 210029
2
Beijing Anzhen Hospital
Beijing, China